Northwestern Medicine Unveils COVID-19’s Role in Advancing Cancer Treatments

Breakthrough in Cancer Treatment Linked to COVID-19

A research team from the Northwestern Medicine Canning Thoracic Institute has found a surprising link between COVID-19 and cancer treatment. Their study, published in The Journal of Clinical Investigation, shows that SARS-CoV-2 RNA can lead to cancer regression, opening the door for new cancer therapies.

Key Findings

The scientists discovered that the RNA from the COVID-19 virus stimulates a type of immune cell with cancer-fighting abilities, called inducible nonclassical monocytes (I-NCMs). These cells actively target cancer cells, hinting at a possible reason for observed cancer shrinkage in some COVID-19 patients.

Dr. Ankit Bharat, the study’s senior author, emphasized the potential: “We found that I-NCMs activated by severe COVID-19 can also be induced with a drug to fight various cancers such as melanoma, lung, breast, and colon cancer.”

Mechanism of Action

During COVID-19, the virus triggers specific immune signals that transform regular monocytes into I-NCMs. These unique cells can penetrate tumor tissue, unlike typical immune cells, allowing them to attack cancer cells directly. Once at the tumor, I-NCMs recruit natural killer cells, which help to destroy the cancerous tissue.

Next Steps

Despite these encouraging results, Dr. Bharat stated that further research is necessary before these findings reach cancer patients. Clinical trials will evaluate the safety and effectiveness of using these immune cells in treating cancer. The aim is to develop strategies for managing challenging cancers that resist current treatments.

This research could also enhance the success of Northwestern’s Double Lung Replacement and Multidisciplinary Care (DREAM) Program, which offers lung transplants for patients with advanced lung cancer. The team hopes to use this research to treat patients effectively without risking new organ rejection.

Conclusion

This discovery presents a promising new approach to cancer treatment. With continued research and clinical trials,
the goal is to create therapies that can significantly impact patients with aggressive cancer types.